Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
DUBLIN- August 14, 2017 - Medtronic plc (NYSE: MDT) today announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) - the combination of aspirin...
DUBLIN - August 2, 2017 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval of its new Avalus(TM) pericardial aortic...
DUBLIN - August 1, 2017 - A new health economic analysis from the landmark FIRE AND ICE Trial, sponsored by Medtronic plc (NYSE: MDT), was published today in the Journal of the American Heart...
DUBLIN - July 31, 2017 - Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic...
DUBLIN - July 30, 2017 - Medtronic plc (NYSE: MDT) today announced that it has completed the previously announced sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional...
DUBLIN - July 17, 2017 - Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of...
DUBLIN - July 11, 2017 - Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing...
DUBLIN - July 10, 2017 - Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic...
DUBLIN and BERLIN - June 28, 2017 - Medtronic plc (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for SureTune(TM)3 software for deep brain stimulation (DBS)....
DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes...